MARLBOROUGH, Mass.,
April 28, 2016 /PRNewswire/ -- Boston
Scientific (NYSE: BSX) today announced key data, including one
late-breaking clinical trial, that will be featured at the 37th
Annual Scientific Sessions of the Heart Rhythm Society (HRS) in
San Francisco on May 4-7.
Data from the EFFORTLESS study, the first large-scale,
multi-national, post-market analysis of safety and efficacy of the
subcutaneous implantable defibrillator (S-ICD), will be featured at
the late-breaking clinical trial session on Friday, May 6. Other presentations and abstracts
of interest include:
- New, pre-clinical data showcasing the company's modular therapy
approach and communications compatibility between its leadless
pacemaker and the EMBLEM™ S-ICD System
- Insights and results of the mapping data obtained using the
high-density, high-resolution Rhythmia™ Mapping System
- Performance and usage information about the ACUITY™ X4
Quadripolar left ventricular (LV) leads, which were approved by the
U.S. Food and Drug Administration (FDA) earlier this year
- Cost-effectiveness and safety data related to the WATCHMAN™
Left Atrial Appendage Closure (LAAC) Device
"We are enthusiastic about the breadth of robust data that we
will be presenting at this year's congress, especially the data
related to the performance of the S-ICD during the late-breaking
clinical trial session" said Kenneth
Stein, M.D., chief medical officer, Rhythm Management,
Boston Scientific. "We are eager to present new evidence supporting
our modular approach to leadless pacing and defibrillation, as well
as proof that our mapping technology continues to set new standards
of performance in the electrophysiology space."
ABSTRACTS OF INTEREST (listed chronologically within
product categories)
Subcutaneous Implantable Defibrillator (S-ICD)
- Session: The Subcutaneous ICD: Improving Efficacy, on
Thursday, May 5 from 1:30 - 3:00 PM, in room 2014, Moscone West.
- First Report On Communicating Leadless Anti-Tachycardia
Pacemaker and Subcutaneous Implantable Defibrillator: Fleur V. Tjong, M.D., will present at
2:30 PM.
- Late-Breaking Clinical Trial: Performance and Outcomes
in Patients with the Subcutaneous Implantable Defibrillator Through
Mid Term Follow-Up: The EFFORTLESS Study: Lucas V. A. Boersma, M.D., Ph.D., will present
on Friday, May 6 at 1:45 PM in room 135, Moscone North.
Rhythmia Mapping System
- Voltage threshold for high density mapping catheter with short
interspaced small electrodes: Frederic
Sacher, M.D., Ph.D., will present on Thursday, May 5 at 1:45
PM in room 3014, Moscone West.
- High-Resolution mapping of Complex Left Atrial Tachycardia:
Initial Experience with the Rhythmia Mapping System: Nicolas Derval, M.D., will present on
Friday, May 6 at 2:30 PM in room 2006, Moscone West.
Cardiac Resynchronization Therapy Defibrillator (CRT-D) and
Implantable Defibrillator (ICD)
- Incidence and Predictors of Phrenic Nerve Stimulation following
Cardiac Resynchronization Therapy System Implantation of a
Quadripolar Lead: Devi G. Nair,
M.D., will present on Friday, May 6
at 1:45 PM in room 2010, Moscone
West.
- Performance and Usage of Proximal Electrodes in Quadripolar
Left Ventricular Pacing Leads: Are All Leads Created Equally?: A
poster authored by Nigel Gupta,
M.D., will be available for viewing
on Friday, May 6 from 2:00 PM – 5:00 PM
in the EPicenter, Hall D.
- The economic impact of longevity of implantable
cardioverter-defibrillator for cardiac resynchronization therapy
from a healthcare service perspective: A poster authored by
Maurizio Landolina, M.D., will be
available for viewing on Saturday, May
7 from 9:00 AM – 12:00 PM in the EPicenter, Hall D.
WATCHMAN LAAC Device
- Safety of Watchman Implantation when Performed with
Uninterrupted Warfarin: A poster authored by Douglas N. Gibson, M.D., will be available for
viewing on Friday, May 6 from
9:00 AM – 12:00 PM in the EPicenter, Hall D.
- A Cost Analysis of Stroke in Non-valvular Atrial Fibrillation:
Left Atrial Appendage Closure versus Warfarin versus Non-warfarin
Oral Anticoagulants: A poster authored by Stacey Amorosi, M.A., and Vivek Y. Reddy, M.D., will be available for
viewing on Friday, May 6 from
2:00 PM – 5:00
PM in the EPicenter, Hall D.
All presentations are listed in Pacific Time and will take place
at Moscone Center. For more information, visit Boston Scientific at
booth #1805.
The company will also host an investor event and webcast on
May 5 from 2:00 – 3:30 PM PDT to provide a presentation and answer
questions from investors about the Boston Scientific rhythm
management portfolio. The event will be accessible via live webcast
at www.bostonscientific.com/investors. A replay of the webcast will
be accessible at www.bostonscientific.com/investors beginning
approximately one hour following the completion of the event.
Caution: The leadless pacemaker is a concept device or
technology and not available for use or sale.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
CONTACTS:
Laura Aumann
Media Relations
Boston Scientific Corporation
(651) 582-4251 (office)
Laura.Aumann@bsci.com
Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
(508) 683-5565 (office)
investor_relations@bsci.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-scheduled-presentations-at-heart-rhythm-society-2016-300259736.html
SOURCE Boston Scientific Corporation